Therapeutic

Therapeutic Thursday: The Field That Keeps Falling Off the Wagon

Obesity just went from the 30th most-studied disease to the 2nd in three years, and almost the entire bet is riding on a single class of drugs.

Jun 18, 2026 Capsul Desk 5 min read members

A scientist in a white lab coat and blue gloves works at a lab bench, holding a pipette and looking down in concentration, with reagent bottles and supplies on the shelves beside him.

Therapeutic Thursday: The Crowd Is The Problem. Everyone Has A Different Solution.

Two of pharma's most crowded fields, and no agreement on whether the answer is to crowd in further or step away.

Jun 11, 2026 Aakash Babu 5 min read members

Therapeutic Thursday: The Deals Are Outrunning the Data in Oncology's Next Wave

Two qualify as first-in-class among 2032's ten biggest oncology bets. So why is big pharma paying nine figures for assets that haven't read out?

Jun 4, 2026 Capsul Desk 7 min read members

Therapeutic Thursday: The Field Is Sorting Itself. Watch Who Is Leaving and Why.

Cell and gene therapy has its first commercial products, its first profitable company, and its first wave of strategic exits. The exits are as informative as the deals.

May 28, 2026 Aakash Babu 13 min read members

Therapeutic Thursday: The ADC Gold Rush Has a Crowding Problem

The clinical logic is sound, the deal volume is real, and the differentiation question is getting harder to ignore.

May 21, 2026 Aakash Babu 7 min read members

Page 1 of 1

Therapeutic Thursday: The Field That Keeps Falling Off the Wagon

Therapeutic Thursday: The Crowd Is The Problem. Everyone Has A Different Solution.

Therapeutic Thursday: The Deals Are Outrunning the Data in Oncology's Next Wave

Therapeutic Thursday: The Field Is Sorting Itself. Watch Who Is Leaving and Why.

Therapeutic Thursday: The ADC Gold Rush Has a Crowding Problem